Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

Ryman and Tower lift NZ sharemarket, but ends lower
Markets Market Close

Ryman and Tower lift NZ sharemarket, but ends lower

The S&P/NZX 50 Index closed down 0.96% or 129.811 points at 13,432.20.

Airports, Jetstar bite back at Air NZ subsidy claim
Markets

Airports, Jetstar bite back at Air NZ subsidy claim

Air NZ is effectively saying 'get what you're given', says Auckland Airport.

Harvey Norman NZ sales up 10%
Markets

Harvey Norman NZ sales up 10%

New Zealand's weak dollar partially offset overseas gains, the company said.

91% of Tower’s new house policies are low flood risk
Markets

91% of Tower’s new house policies are low flood risk

Shareholders will get an increased dividend on top of a $45m capital return.